Amicus raises FY18 Galafold revenue guidance $80M-$90M from $75M-$85M
Revenue consensus $85.21M. For FY18 the company is increasing its total Galafold revenue guidance to $80M to $90M from the previous range of $75M to $85M. This reflects global revenue from all expected 2018 commercial markets. Based on the increase in expected 2018 revenue and operating expenses that are trending favorably to budget, the Company is updating its full-year 2018 net cash spend to $220M to $250M from the previous range of $230M to $260M. The current cash position, including proceeds from the February 2018 equity offering and expected Galafold revenues, is sufficient to fund ongoing Fabry and Pompe program operations into at least 2021. Potential future business development collaborations, pipeline expansion, and investment in biologics manufacturing capabilities could impact the Company's future capital requirements.